Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

<p><strong>Background</strong> There have been no studies of the patterns of post-marketing withdrawals of medicinal products to which adverse reactions have been attributed. We identified medicinal products that were withdrawn because of adverse drug reactions, examined the eviden...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Onakpoya, IJ, Heneghan, CJ, Aronson, JK
Format:	Journal article
Język:	English
Wydane:	BioMed Central 2016

Podobne zapisy

Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
od: Igho J. Onakpoya, i wsp.
Wydane: (2019-03-01)

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
od: Onakpoya, I, i wsp.
Wydane: (2016)

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
od: Onakpoya, I, i wsp.
Wydane: (2017)

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
od: Onakpoya, I, i wsp.
Wydane: (2016)

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
od: Onakpoya, I, i wsp.
Wydane: (2017)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
od: Onakpoya, I
Wydane: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
od: Onakpoya, I, i wsp.
Wydane: (2017)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
od: Onakpoya, IJ, i wsp.
Wydane: (2020)

Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
od: Daniele Sartori, i wsp.
Wydane: (2020-08-01)

Withdrawal of cerivastatin from the world market
od: Pitt Bertram, i wsp.
Wydane: (2001-09-01)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
od: Onakpoya, I, i wsp.
Wydane: (2018)

Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
od: Aronson, J
Wydane: (2017)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
od: Aronson, J
Wydane: (2008)

Transmission of SARS-CoV-2 from pre and asymptomatic infected individuals: a systematic review update
od: Jefferson, T, i wsp.
Wydane: (2022)

An agenda for research on adverse drug reactions.
od: Aronson, J
Wydane: (2007)

Adverse drug reactions--no farewell to harms.
od: Aronson, J
Wydane: (2007)

Pharmacogenetics and adverse drug reactions
od: Ferner, R, i wsp.
Wydane: (2010)

REG 462 - Rekabentuk Konkrit
od: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Wydane: (1995)

Withdrawn medicines included in the essential medicines lists of 136 countries.
od: Onella Charles, i wsp.
Wydane: (2019-01-01)

Recommendations of high-quality clinical practice guidelines related to the process of starting dialysis: a systematic review
od: Salas-Gama, K, i wsp.
Wydane: (2022)

20.462J / 3.962J Molecular Principles of Biomaterials (BE.462J), Spring 2003
od: Irvine, Darrell J.
Wydane: (2003)

The effectiveness and safety of Japanese traditional medicine (Kampo) in the treatment of climacteric symptoms
od: Onakpoya, I, i wsp.
Wydane: (2013)

Adverse drug reactions: definitions, diagnosis, and management.
od: Edwards, I, i wsp.
Wydane: (2000)

What evidence affects clinical practice? An analysis of Evidence-Based Medicine commentaries
od: Coombs, C, i wsp.
Wydane: (2017)

Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity
od: Ferner, RE, i wsp.
Wydane: (2022)

Adverse drug reactions: keeping up to date.
od: Aronson, J, i wsp.
Wydane: (2002)

Is It Because I Can or Because of Who I Am?
od: María Laura Gonzalez-Canosa, i wsp.
Wydane: (2021-12-01)

Paradoxical reactions: Under-recognized adverse effects of drugs?
od: Hauben, M, i wsp.
Wydane: (2006)

National differences in publishing papers on adverse drug reactions.
od: Ferner, R, i wsp.
Wydane: (2005)

RMK462 - PENTADBIRAN TANAH FEBRUARI 1998
od: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Wydane: (1998)

REG 462 - REKABENTUK KONKRIT JUN 1992
od: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Wydane: (1992)

PGT 462: Pengelolaan Dan Penyelidikan Sekolah
od: PPIP, Pusat Pengajian Ilmu Pendidikan
Wydane: (1997)

PGT 462 Pengelolaan dan Penyeliaan Sekolah
od: PPIP, Pusat Pengajian Ilmu Pendidikan
Wydane: (1997)

Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability
od: Aronson, J
Wydane: (2012)

Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993–2016
od: Johanna Seifert, i wsp.
Wydane: (2024-11-01)

The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance
od: Łukasz Dobrek
Wydane: (2022-08-01)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
od: Talbot, J, i wsp.
Wydane: (2012)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
od: Talbot, J, i wsp.
Wydane: (2012)

SARS-CoV-2 and the role of orofecal transmission: a systematic review
od: Heneghan, CJ, i wsp.
Wydane: (2021)

SARS-CoV-2 and the role of fomite transmission: a systematic review
od: Onakpoya, IJ, i wsp.
Wydane: (2021)